At the time of writing, Genmab ADR [GMAB] stock is trading at $19.58, down -1.61%. An important factor to consider is whether the stock is rising or falling in short-term value. The GMAB shares have gain 1.50% over the last week, with a monthly amount drifted -13.67%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Genmab ADR [NASDAQ: GMAB] stock has seen the most recent analyst activity on March 11, 2025, when William Blair upgraded its rating to a Outperform. Previously, Leerink Partners upgraded its rating to Outperform on February 13, 2025, and kept the price target unchanged to $27. On October 08, 2024, Redburn Atlantic initiated with a Buy rating. JP Morgan downgraded its rating to a Neutral. RBC Capital Mkts upgraded its rating to Outperform for this stock on July 15, 2024. In a note dated February 23, 2024, BMO Capital Markets upgraded an Outperform rating on this stock and boosted its target price from $46 to $48.
For the past year, the stock price of Genmab ADR fluctuated between $18.64 and $30.50. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. Genmab ADR [NASDAQ: GMAB] shares were valued at $19.58 at the most recent close of the market. An investor can expect a potential return of 129.83% based on the average GMAB price forecast.
Analyzing the GMAB fundamentals
According to Genmab ADR [NASDAQ:GMAB], the company’s sales were 3.12B for trailing twelve months, which represents an 36.55% jump. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.43%, and Net Profit Margin reading is 0.36%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.24 and Total Capital is 0.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.40 points at the first support level, and at 19.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.71, and for the 2nd resistance point, it is at 19.84.
Ratios To Look Out For
It is important to note that Genmab ADR [NASDAQ:GMAB] has a current ratio of 5.25. On the other hand, the Quick Ratio is 5.24, and the Cash Ratio is 1.86. Considering the valuation of this stock, the price to sales ratio is 3.99, the price to book ratio is 2.44 and price to earnings (TTM) ratio is 11.18.
